{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:46:15Z","timestamp":1793400375820,"version":"4.5.0"},"reference-count":178,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Dysregulated cell cycle progression is a well-established hallmark of cancer, driving the development of targeted antitumor therapies that intervene at specific phases of the cell cycle. Among these therapeutic targets, cyclin-dependent kinases 4 and 6 (CDK4\/6) have emerged as critical regulators of cell cycle progression, with their aberrant activation being strongly implicated in tumorigenesis and cancer progression. Currently, multiple CDK4\/6 inhibitors have received clinical approval for hormone receptor (HR)-positive\/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, demonstrating dual therapeutic mechanisms through both cell cycle arrest and enhancement of antitumor immunity. However, clinical implementation faces two major challenges: the inevitable development of acquired resistance during prolonged treatment, and the need for optimized combination strategies with other anticancer agents to achieve synergistic efficacy. This review systematically examines the molecular mechanisms underlying CDK4\/6 inhibitor function and characterizes currently approved therapeutic agents. Importantly, it synthesizes recent discoveries regarding resistance mechanisms, including dysregulated cell cycle checkpoints, compensatory signaling pathway activation, and tumor microenvironment adaptations. Furthermore, we critically evaluate emerging combination therapeutic approaches targeting these resistance mechanisms. By integrating mechanistic insights with clinical evidence, this analysis aims to provide actionable strategies for overcoming therapeutic resistance and maximizing the clinical potential of CDK4\/6 inhibitors in breast cancer management.<\/jats:p>","DOI":"10.3389\/fphar.2025.1549520","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T02:07:40Z","timestamp":1747015660000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["CDK4\/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Tong","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673345472250301052255","article-title":"Analysis of the main directions in the development of mono and combination pharmacotherapy acting on hormonal signaling pathways of breast cancer according to the FDA databases and Clinicaltrials.gov","volume":"32","author":"Abdullaeva","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41698-023-00360-5","article-title":"AKT\/mTOR signaling modulates resistance to endocrine therapy and CDK4\/6 inhibition in metastatic breast cancers","volume":"7","author":"Abu-Khalaf","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1158\/1078-0432.CCR-22-1281","article-title":"Palbociclib rechallenge for hormone receptor-positive\/HER-negative advanced breast cancer: findings from the phase II BioPER trial","volume":"29","author":"Albanell","year":"2023","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Cancer cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1078-0432.CCR-18-1999","article-title":"To cycle or fight-CDK4\/6 inhibitors at the crossroads of anticancer immunity","volume":"25","author":"Ameratunga","year":"2019","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann. Oncol. official J. Eur. Soc. Med. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.annonc.2023.08.011","article-title":"Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials","volume":"34","author":"Andr\u00e9","year":"2023","journal-title":"Ann. Oncol. official J. Eur. Soc. Med. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1158\/1078-0432.CCR-18-0162","article-title":"Targeted therapy for premenopausal women with HR(+), HER2(-) advanced breast cancer: focus on special considerations and latest advances","volume":"24","author":"Bardia","year":"2018","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1158\/1078-0432.CCR-20-2114","article-title":"Phase I\/II trial of exemestane, ribociclib, and everolimus in women with HR(+)\/HER2(-) advanced breast cancer after progression on CDK4\/6 inhibitors (TRINITI-1)","volume":"27","author":"Bardia","year":"2021","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/med.21856","article-title":"Analyzing the scaffold diversity of cyclin-dependent kinase inhibitors and revisiting the clinical and preclinical pipeline","volume":"42","author":"Bhurta","year":"2022","journal-title":"Med. Res. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/1535-7163.MCT-15-0775","article-title":"Preclinical characterization of G1T28: a novel CDK4\/6 inhibitor for reduction of chemotherapy-induced myelosuppression","volume":"15","author":"Bisi","year":"2016","journal-title":"Mol. cancer Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","article-title":"Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer","volume":"25","author":"Browne","year":"2024","journal-title":"Lancet Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40273-018-0708-4","article-title":"Ribociclib with an aromatase inhibitor for previously untreated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer: an evidence review group perspective of a NICE single technology appraisal","volume":"37","author":"B\u00fcy\u00fckkaramikli","year":"2019","journal-title":"PharmacoEconomics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11427-021-2140-8","article-title":"Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4\/6 inhibitor in breast cancer that can be reversed by PI3K\/mTOR inhibitors","volume":"66","author":"Cai","year":"2023","journal-title":"Sci. China Life Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1158\/0008-5472.CAN-18-1235","article-title":"Low-molecular-weight cyclin E in human cancer: cellular consequences and opportunities for targeted therapies","volume":"78","author":"Caruso","year":"2018","journal-title":"Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2017-11-742577","article-title":"The MYC oncogene is a global regulator of the immune response","volume":"131","author":"Casey","year":"2018","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Sci. (New York, NY)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10549-019-05261-5","article-title":"Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success","volume":"176","author":"Cazzaniga","year":"2019","journal-title":"Breast cancer Res. Treat."},{"key":"B22","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/neuonc\/nos114","article-title":"p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells","volume":"14","author":"Cen","year":"2012","journal-title":"Neuro-oncology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S1875-5364(25)60846-6","article-title":"Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment","volume":"23","author":"Chen","year":"2025","journal-title":"Chin. J. Of Nat. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1470-2045(23)00228-0","article-title":"Dalpiciclib in advanced breast cancer","volume":"24","author":"Chen","year":"2023","journal-title":"Lancet Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann. Oncol. official J. Eur. Soc. Med. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2217\/fon-2023-0513","article-title":"The impact of myelosuppression on quality of life of patients treated with chemotherapy","volume":"20","author":"Crawford","year":"2024","journal-title":"Future Oncol. Lond. Engl."},{"key":"B27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/CCO.0000000000000952","article-title":"The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps","volume":"35","author":"Crawford","year":"2023","journal-title":"Curr. Opin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/cells8060614","article-title":"Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"key":"B30","doi-asserted-by":"publisher","first-page":"29075","DOI":"10.1074\/jbc.M112.365494","article-title":"Modification of the DNA damage response by therapeutic CDK4\/6 inhibition","volume":"287","author":"Dean","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"key":"B32","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","article-title":"Trilaciclib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41568-018-0008-5","article-title":"Non-canonical functions of the RB protein in cancer","volume":"18","author":"Dick","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"7288","DOI":"10.1158\/1078-0432.CCR-17-1544","article-title":"Cytoplasmic cyclin E mediates resistance to aromatase inhibitors in breast cancer","volume":"23","author":"Doostan","year":"2017","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev-cancerbio-030518-055552","article-title":"Cancer immunotherapy: beyond checkpoint blockade","volume":"3","author":"Dougan","year":"2019","journal-title":"Annu. Rev. cancer Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/molecules21070965","article-title":"Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer","volume":"21","author":"Du","year":"2016","journal-title":"Mol. Basel, Switz."},{"key":"B37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2023.0137","article-title":"Current progress in cancer treatment by targeting FGFR signaling","volume":"20","author":"Du","year":"2023","journal-title":"Cancer Biol. & Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"107508","DOI":"10.1016\/j.bioorg.2024.107508","article-title":"Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment","volume":"149","author":"Dubey","year":"2024","journal-title":"Bioorg. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1158\/0008-5472.CAN-07-0200","article-title":"Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin","volume":"67","author":"Efeyan","year":"2007","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/14737140.2020.1834385","article-title":"Abemaciclib, a third CDK 4\/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer","volume":"21","author":"El","year":"2021","journal-title":"Expert Rev. anticancer Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell death Differ."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1111\/jgs.18350","article-title":"Cell cycle arrest: a breakthrough in the supportive care of older cancer patients","volume":"71","author":"Falandry","year":"2023","journal-title":"J. Am. Geriatrics Soc."},{"key":"B43","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"B44","doi-asserted-by":"publisher","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Sci. (New York, NY)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast cancer Res. BCR"},{"key":"B46","doi-asserted-by":"publisher","first-page":"103863","DOI":"10.1016\/j.breast.2024.103863","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors (CDK4\/6i): mechanisms of resistance and where to find them","volume":"79","author":"Foffano","year":"2025","journal-title":"Breast"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat. Commun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/1535-7163.MCT-17-0040","article-title":"CDK4\/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell-cycle arrest","volume":"16","author":"Francis","year":"2017","journal-title":"Mol. cancer Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"bqab235","DOI":"10.1210\/endocr\/bqab235","article-title":"Interferon signaling in estrogen receptor-positive breast cancer: a revitalized topic","volume":"163","author":"Fu","year":"2022","journal-title":"Endocrinology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1038\/s41467-020-16170-3","article-title":"Acquired resistance to combined BET and CDK4\/6 inhibition in triple-negative breast cancer","volume":"11","author":"Ge","year":"2020","journal-title":"Nat. Commun."},{"key":"B52","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14740338.2020.1781814","article-title":"Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor","volume":"19","author":"Gebbia","year":"2020","journal-title":"Expert Opin. drug Saf."},{"key":"B53","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","article-title":"Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors","volume":"29","author":"Goel","year":"2016","journal-title":"Cancer cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1007\/s12325-023-02601-2","article-title":"Real-world outcomes of trilaciclib among patients with extensive-stage small cell lung cancer receiving chemotherapy","volume":"40","author":"Goldschmidt","year":"2023","journal-title":"Adv. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"100559","DOI":"10.1016\/j.medj.2024.11.012","article-title":"Targeting autophagy plus high-dose CDK4\/6 inhibitors in advanced HR+HER2-breast cancer: a phase 1b\/2 trial","author":"Gong","year":"2024","journal-title":"Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","article-title":"Combination therapies with CDK4\/6 inhibitors to treat KRAS-mutant pancreatic cancer","volume":"83","author":"Goodwin","year":"2023","journal-title":"Cancer Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B59","doi-asserted-by":"publisher","first-page":"eaaw2106","DOI":"10.1126\/science.aaw2106","article-title":"p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition","volume":"366","author":"Guiley","year":"2019","journal-title":"Sci. (New York, NY)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41388-025-03378-0","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment","volume":"44","author":"Guo","year":"2025","journal-title":"Oncogene"},{"key":"B61","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1530391","DOI":"10.3389\/fonc.2025.1530391","article-title":"Real-world effectiveness of CDK4\/6i in first-line treatment of HR+\/HER2-advanced\/metastatic breast cancer: updated systematic review","volume":"15","author":"Harbeck","year":"2025","journal-title":"Front. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/neuonc\/now106","article-title":"Inhibition of DNA damage repair by the CDK4\/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth","volume":"18","author":"Hashizume","year":"2016","journal-title":"Neuro-oncology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"eaal3986","DOI":"10.1126\/scitranslmed.aal3986","article-title":"Transient CDK4\/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion","volume":"9","author":"He","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/2159-8290.CD-20-1540","article-title":"Inhibition of CDK4\/6 promotes CD8 T-cell memory formation","volume":"11","author":"Heckler","year":"2021","journal-title":"Cancer Discov."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1158\/0008-5472.CAN-13-2923","article-title":"CDK4\/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers","volume":"74","author":"Heilmann","year":"2014","journal-title":"Cancer Res."},{"key":"B67","first-page":"3573","volume-title":"Non-Smad TGF-beta signals","author":"Heldin","year":"2005"},{"key":"B68","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann. Oncol. official J. Eur. Soc. Med. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1200\/JCO.18.02217","article-title":"Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4\/6 inhibitor and an aromatase inhibitor: an FDA pooled analysis","volume":"37","author":"Howie","year":"2019","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"9495","DOI":"10.1126\/sciadv.adq9495","article-title":"Proteogenomic discovery of RB1-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets","volume":"11","author":"Iacovacci","year":"2025","journal-title":"Sci. Adv."},{"key":"B72","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40262-023-01338-z","article-title":"Use of pharmacokinetic and pharmacodynamic data to develop the CDK4\/6 inhibitor ribociclib for patients with advanced breast cancer","volume":"63","author":"Ji","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"B74","doi-asserted-by":"publisher","first-page":"12765","DOI":"10.1038\/s41598-025-97504-3","article-title":"Cost-effectiveness of CDK4\/6 inhibitors for second-line HR+\/HER2-advanced or metastatic breast cancer in China","volume":"15","author":"Jia","year":"2025","journal-title":"Sci. Rep."},{"key":"B75","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","article-title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Jiang","year":"2019","journal-title":"Lancet Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.semcdb.2020.05.001","article-title":"Role of cyclins and cyclin-dependent kinases in pluripotent stem cells and their potential as a therapeutic target","volume":"107","author":"Jirawatnotai","year":"2020","journal-title":"Seminars cell & Dev. Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"LBA1004","DOI":"10.1200\/jco.2022.40.17_suppl.lba1004","article-title":"A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4\/6 inhibition (CDK 4\/6i) in patients (pts) with unresectable or hormone receptor\u2013positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial","volume":"40","author":"Kalinsky","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12282-017-0818-4","article-title":"Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis","volume":"25","author":"Kassem","year":"2018","journal-title":"Breast cancer Tokyo, Jpn."},{"key":"B79","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1093\/nar\/gkg406","article-title":"Transcription of mouse DNA methyltransferase 1 (Dnmt1) is regulated by both E2F-Rb-HDAC-dependent and -independent pathways","volume":"31","author":"Kimura","year":"2003","journal-title":"Nucleic acids Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccell.2018.03.023","article-title":"CDK4\/6 inhibitors: the mechanism of action may not Be as simple as once thought","volume":"34","author":"Klein","year":"2018","journal-title":"Cancer cell"},{"key":"B81","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-023-06069-6","article-title":"The complementarity of DDR, nucleic acids and anti-tumour immunity","volume":"619","author":"Kornepati","year":"2023","journal-title":"Nature"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3390\/cancers17061039","article-title":"CDK4\/6 as a therapeutic target in HR+\/HER2- breast cancer cells-current treatment status","volume":"17","author":"Krupa","year":"2025","journal-title":"Cancers (Basel)."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/nm.2941","article-title":"Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma","volume":"18","author":"Kwong","year":"2012","journal-title":"Nat. Med."},{"key":"B84","first-page":"178","volume-title":"Molecular mechanisms of epithelial-mesenchymal transition","author":"Lamouille","year":"2014"},{"key":"B85","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/genes11040467","article-title":"Transcriptomic profiling identifies differentially expressed genes in palbociclib-resistant ER+ MCF7 breast cancer cells","volume":"11","author":"Lanceta","year":"2020","journal-title":"Genes"},{"key":"B86","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13045-017-0482-3","article-title":"Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas","volume":"10","author":"Laroche-Clary","year":"2017","journal-title":"J. Hematol. & Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1101\/gad.9.6.639","article-title":"Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution","volume":"9","author":"Lee","year":"1995","journal-title":"Genes & Dev."},{"key":"B88","doi-asserted-by":"publisher","first-page":"17588359211022890","DOI":"10.1177\/17588359211022890","article-title":"A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+\/HER2-metastatic breast cancer","volume":"13","author":"Li","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1101\/gad.315648.118","article-title":"Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4\/6is","volume":"32","author":"Liao","year":"2018","journal-title":"Genes & Dev."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20221082","article-title":"INK4 cyclin-dependent kinase inhibitors as potential prognostic biomarkers and therapeutic targets in hepatocellular carcinoma","volume":"42","author":"Liu","year":"2022","journal-title":"Biosci. Rep."},{"key":"B91","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cancers17010016","article-title":"New emerging therapies targeting PI3K\/AKT\/mTOR\/PTEN pathway in hormonal receptor-positive and HER2-negative breast cancer-current state and molecular pathology perspective","volume":"17","author":"Liu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B92","doi-asserted-by":"publisher","first-page":"eaaw9450","DOI":"10.1126\/scisignal.aaw9450","article-title":"KRAS(G12C) inhibition produces a driver-limited state revealing collateral dependencies","volume":"12","author":"Lou","year":"2019","journal-title":"Sci. Signal."},{"key":"B93","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nri1632","article-title":"NFAT proteins: key regulators of T-cell development and function","volume":"5","author":"Macian","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cell.2004.08.002","article-title":"Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6","volume":"118","author":"Malumbres","year":"2004","journal-title":"Cell"},{"key":"B95","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10549-023-07002-1","article-title":"Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El \u00c1lamo IV registry","volume":"201","author":"Mart\u00edn","year":"2023","journal-title":"Breast cancer Res. Treat."},{"key":"B96","doi-asserted-by":"publisher","first-page":"20420986231224214","DOI":"10.1177\/20420986231224214","article-title":"Abemaciclib pharmacology and interactions in the treatment of HR+\/HER2-breast cancer: a critical review","volume":"15","author":"Martorana","year":"2024","journal-title":"Ther. Adv. drug Saf."},{"key":"B97","doi-asserted-by":"publisher","first-page":"OT2","DOI":"10.1158\/1538-7445.sabcs19-ot2-04-07","article-title":"Abstract OT2-04-07: phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial)","volume":"80","author":"Masuda","year":"2020","journal-title":"NEWFLAME trial"},{"key":"B98","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 kinase in cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat. Rev. Mol. cell Biol."},{"key":"B100","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS17-OT3-05-11","volume-title":"Abstract OT3-05-11: palbociclib after CDK inhibitor and endocrine therapy (PACE): a randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+\/HER2-metastatic breast cancer","author":"Mayer","year":"2018"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1758835918793849","DOI":"10.1177\/1758835918793849","article-title":"Updates on managing advanced breast cancer with palbociclib combination therapy","volume":"10","author":"McShane","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","article-title":"ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer","volume":"1","author":"Miller","year":"2011","journal-title":"Cancer Discov."},{"key":"B103","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-022-01642-5","article-title":"S6K1 amplification confers innate resistance to CDK4\/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer","volume":"21","author":"Mo","year":"2022","journal-title":"Mol. cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03896-z","article-title":"CDK4\/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists' perceptions","author":"Moreno","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.3390\/cancers15184611","article-title":"Editorial for the special issue \u201cbreast cancer-therapeutic challenges, research strategies and novel diagnostics\u201d","volume":"15","author":"Nabieva","year":"2023","journal-title":"Cancers"},{"key":"B106","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/ni.2886","article-title":"The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells","volume":"15","author":"Obata","year":"2014","journal-title":"Nat. Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13058-020-01320-8","article-title":"Targeting activated PI3K\/mTOR signaling overcomes acquired resistance to CDK4\/6-based therapies in preclinical models of hormone receptor-positive breast cancer","volume":"22","author":"O'Brien","year":"2020","journal-title":"Breast cancer Res. BCR"},{"key":"B108","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12282-020-01150-8","article-title":"Resistance to cyclin-dependent kinase (CDK) 4\/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells","volume":"28","author":"Ogata","year":"2021","journal-title":"Breast cancer Tokyo, Jpn."},{"key":"B109","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2147\/BCTT.S271441","article-title":"Practical guidance on abemaciclib in combination with adjuvant endocrine therapy for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative high-risk early breast cancer","volume":"16","author":"O'Keefe","year":"2024","journal-title":"Breast cancer (Dove Med. Press)"},{"key":"B110","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-14-2955","article-title":"CDK4 amplification reduces sensitivity to CDK4\/6 inhibition in fusion-positive rhabdomyosarcoma","volume":"21","author":"Olanich","year":"2015","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/jnci\/djaa087","article-title":"Circulating tumor DNA markers for early progression on fulvestrant with or without palbociclib in ER+ advanced breast cancer","volume":"113","author":"O'Leary","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O'Leary","year":"2018","journal-title":"Cancer Discov."},{"key":"B113","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40273-023-01259-6","article-title":"Abemaciclib in combination with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer: an evidence review group perspective of a NICE single technology appraisal","volume":"41","author":"Orozco Leal","year":"2023","journal-title":"PharmacoEconomics"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: a review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int. J. cancer"},{"key":"B115","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/genes12020159","article-title":"Deregulated immune pathway associated with palbociclib resistance in preclinical breast cancer models: integrative genomics and transcriptomics","volume":"12","author":"Pandey","year":"2021","journal-title":"Genes"},{"key":"B116","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/BCTT.S341857","article-title":"Ribociclib in the treatment of hormone-receptor positive\/HER2-negative advanced and early breast cancer: overview of clinical data and patients selection","volume":"14","author":"Parati","year":"2022","journal-title":"Breast cancer (Dove Med. Press)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1055\/s-0044-1791768","article-title":"Consensus Guidelines for the use of cyclin-dependent kinase (CDK) 4\/6 inhibitors in the management of hormone receptor positive (HR+ve), her2-ve early breast cancer (EBC)","volume":"14","author":"Parikh","year":"2024","journal-title":"South Asian J. Cancer"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S1470-2045(19)30565-0","article-title":"Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial","volume":"20","author":"Park","year":"2019","journal-title":"Lancet Oncol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"777867","DOI":"10.3389\/fonc.2021.777867","article-title":"MDM2 as a rational target for intervention in CDK4\/6 inhibitor resistant, hormone receptor positive breast cancer","volume":"11","author":"Portman","year":"2021","journal-title":"Front. Oncol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3390\/cancers11091242","article-title":"The PI3K\/AKT\/mTOR and CDK4\/6 pathways in endocrine resistant HR+\/HER2- metastatic breast cancer: biological mechanisms and new treatments","volume":"11","author":"Presti","year":"2019","journal-title":"Cancers"},{"key":"B121","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/03007995.2018.1519500","article-title":"Predictors of systemic therapy sequences following a CDK 4\/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer","volume":"35","author":"Princic","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"B122","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3390\/biomedicines10030685","article-title":"Targeting CDK4\/6 for anticancer therapy","volume":"10","author":"Qi","year":"2022","journal-title":"Biomedicines"},{"key":"B123","doi-asserted-by":"publisher","first-page":"e00377","DOI":"10.1042\/BSR20160152","article-title":"APC\/C and retinoblastoma interaction: cross-talk of retinoblastoma protein with the ubiquitin proteasome pathway","volume":"36","author":"Ramanujan","year":"2016","journal-title":"Biosci. Rep."},{"key":"B124","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40487-024-00295-2","article-title":"Palbociclib in HR-positive, HER2-negative advanced\/metastatic breast cancer: a systematic scoping review of real-world evidence from countries outside of western regions that are underrepresented in clinical trials","volume":"12","author":"Rauthan","year":"2024","journal-title":"Oncol. Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/17425255.2019.1559816","article-title":"Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer","volume":"15","author":"Robert","year":"2019","journal-title":"Expert Opin. drug metabolism & Toxicol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1158\/1535-7163.MCT-18-1161","article-title":"Chemotherapy and CDK4\/6 inhibitors: unexpected bedfellows","volume":"19","author":"Roberts","year":"2020","journal-title":"Mol. cancer Ther."},{"key":"B127","first-page":"31","volume-title":"Histone deacetylase inhibitors in cancer therapy","author":"Rosato","year":"2003"},{"key":"B128","doi-asserted-by":"publisher","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B129","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B130","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.molcel.2020.08.020","article-title":"Integrating old and new paradigms of G1\/S control","volume":"80","author":"Rubin","year":"2020","journal-title":"Mol. cell"},{"key":"B131","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/fon-2023-0407","article-title":"The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results","volume":"20","author":"Rugo","year":"2024","journal-title":"Future Oncol. Lond. Engl."},{"key":"B132","doi-asserted-by":"publisher","first-page":"102924","DOI":"10.1016\/j.ctrv.2025.102924","article-title":"Post-progression treatment options after CDK4\/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"135","author":"Sahin","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"B133","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2020.01.007","article-title":"CDK4\/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma","volume":"37","author":"Salvador-Barbero","year":"2020","journal-title":"Cancer cell"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e240111","DOI":"10.57264\/cer-2024-0111","article-title":"A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib","volume":"13","author":"Samjoo","year":"2024","journal-title":"J. Comp. Eff. Res."},{"key":"B135","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14737140.2022.2052277","article-title":"Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials","volume":"22","author":"San\u00f2","year":"2022","journal-title":"Expert Rev. anticancer Ther."},{"key":"B136","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.molcel.2013.04.003","article-title":"A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression","volume":"50","author":"Schachter","year":"2013","journal-title":"Mol. cell"},{"key":"B137","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Rep."},{"key":"B138","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-19-0253","article-title":"The ongoing search for biomarkers of CDK4\/6 inhibitor responsiveness in breast cancer","volume":"19","author":"Schoninger","year":"2020","journal-title":"Mol. cancer Ther."},{"key":"B139","doi-asserted-by":"publisher","first-page":"e900","DOI":"10.1634\/theoncologist.2019-0729","article-title":"Hormone receptor-positive\/human epidermal growth receptor 2-negative metastatic breast cancer in young women: emerging data in the era of molecularly targeted agents","volume":"25","author":"Shah","year":"2020","journal-title":"Oncol."},{"key":"B140","first-page":"505","article-title":"Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines","volume":"55","author":"Shapiro","year":"1995","journal-title":"Cancer Res."},{"key":"B141","doi-asserted-by":"publisher","first-page":"108095","DOI":"10.1016\/j.bioorg.2024.108095","article-title":"CDK4\/6 inhibitors in HR-positive breast cancer immunotherapy","volume":"154","author":"Shen","year":"2025","journal-title":"Bioorg. Chem."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes & Dev."},{"key":"B143","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12916-024-03431-x","article-title":"The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4\/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification","volume":"22","author":"Shi","year":"2024","journal-title":"BMC Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","article-title":"EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer","volume":"29","author":"Singh","year":"2010","journal-title":"Oncogene"},{"key":"B145","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/cells8040321","article-title":"Updates on the CDK4\/6 inhibitory strategy and combinations in breast cancer","volume":"8","author":"Sobhani","year":"2019","journal-title":"Cells"},{"key":"B146","doi-asserted-by":"publisher","first-page":"eabq4293","DOI":"10.1126\/sciadv.abq4293","article-title":"The spindle assembly checkpoint is a therapeutic vulnerability of CDK4\/6 inhibitor-resistant ER(+) breast cancer with mitotic aberrations","volume":"8","author":"Soria-Bretones","year":"2022","journal-title":"Sci. Adv."},{"key":"B147","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet London, Engl."},{"key":"B148","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/medicina59040696","article-title":"Does the rechallenge with another CDK 4\/6 inhibitor in breast cancer work? A case report and literature review","volume":"59","author":"Stanciu","year":"2023","journal-title":"Med. Kaunas. Lith."},{"key":"B149","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41523-018-0068-4","article-title":"Cdk4\/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer","volume":"4","author":"Tanguy","year":"2018","journal-title":"NPJ breast cancer"},{"key":"B150","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/cpdd.1182","article-title":"A randomized, open-label, phase I clinical study of dalpiciclib with different specifications after process modification in healthy Chinese volunteers","volume":"12","author":"Tao","year":"2023","journal-title":"Clin. Pharmacol. drug Dev."},{"key":"B151","doi-asserted-by":"publisher","first-page":"940","DOI":"10.15252\/msb.20167321","article-title":"De novo MYC addiction as an adaptive response of cancer cells to CDK4\/6 inhibition","volume":"13","author":"Tarrado-Castellarnau","year":"2017","journal-title":"Mol. Syst. Biol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"B153","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925","article-title":"Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer","volume":"37","author":"Turner","year":"2019","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/biomedicines13030546","article-title":"Real-world analysis of adherence to abemaciclib and endocrine therapy in women with HR+\/HER2- breast cancer","volume":"13","author":"Valerio","year":"2025","journal-title":"Biomedicines"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cell.2019.03.030","article-title":"Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities","volume":"177","author":"Vasaikar","year":"2019","journal-title":"Cell"},{"key":"B159","doi-asserted-by":"publisher","first-page":"15916","DOI":"10.1038\/ncomms15916","article-title":"CDK4\/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers","volume":"8","author":"Vijayaraghavan","year":"2017","journal-title":"Nat. Commun."},{"key":"B160","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","article-title":"CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors","volume":"26","author":"Vora","year":"2014","journal-title":"Cancer cell"},{"key":"B161","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1358\/dof.2022.47.12.3448339","article-title":"Dalpiciclib. Cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor, Treatment of HR+\/HER2\u2212 and HER2+ advanced breast cancer","volume":"47","author":"Wang","year":"2022","journal-title":"Drugs Future"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/tbj.13703","article-title":"CDK4\/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+\/HER2-breast cancer: a meta-analysis of randomized controlled trials","volume":"26","author":"Wang","year":"2020","journal-title":"breast J."},{"key":"B163","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/j.seminoncol.2024.01.002","article-title":"CDK4\/6 inhibitors in the treatment of metastatic breast cancer: focus on toxicity and safety","volume":"50","author":"Wekking","year":"2023","journal-title":"Seminars Oncol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.2147\/CMAR.S250632","article-title":"Current therapeutic progress of CDK4\/6 inhibitors in breast cancer","volume":"12","author":"Wu","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"141","DOI":"10.6004\/jnccn.2018.7094","article-title":"Retrospective analysis of treatment patterns and effectiveness of palbociclib and subsequent regimens in metastatic breast cancer","volume":"17","author":"Xi","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"B166","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/onc.2016.379","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"key":"B167","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1038\/onc.2008.165","article-title":"Rb\/E2F4 and Smad2\/3 link survivin to TGF-beta-induced apoptosis and tumor progression","volume":"27","author":"Yang","year":"2008","journal-title":"Oncogene"},{"key":"B168","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/tbcr-21-36","article-title":"A narrative review of the clinical development of CDK4\/6 inhibitor abemaciclib in breast cancer","volume":"3","author":"Yang","year":"2022","journal-title":"Transl. breast cancer Res. a J. Focus. Transl. Res. breast cancer"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/jcph.1415","article-title":"A phase 1 mass balance study of 14 C-labeled talazoparib in patients with advanced solid tumors","volume":"59","author":"Yanke","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"6930","DOI":"10.1021\/jm5004733","article-title":"Small molecule inhibitors targeting activator protein 1 (AP-1)","volume":"57","author":"Ye","year":"2014","journal-title":"J. Med. Chem."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/1541-7786.MCR-09-0537","article-title":"Cyclin-dependent kinase 4-mediated phosphorylation inhibits Smad3 activity in cyclin D-overexpressing breast cancer cells","volume":"8","author":"Zelivianski","year":"2010","journal-title":"Mol. cancer Res. MCR"},{"key":"B172","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1472407","DOI":"10.3389\/fonc.2025.1472407","article-title":"A meta-analysis and systematic review of different cyclin-dependent kinase 4\/6 inhibitors in breast cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Front. Oncol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-021-00271-2","article-title":"A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4\/6 inhibitor in Chinese patients with advanced breast cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomark. Res."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.21037\/tcr-22-2807","article-title":"A narrative review about CDK4\/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer","volume":"12","author":"Zhao","year":"2023","journal-title":"Transl. cancer Res."},{"key":"B176","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.breast.2022.10.018","article-title":"Clinical outcomes of tucidinostat-based therapy after prior CDK4\/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer","volume":"66","author":"Zhou","year":"2022","journal-title":"Breastedinbg. Scotl."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/0008-5472.CAN-20-2828","article-title":"HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4\/6 inhibitor resistance in cancer","volume":"81","author":"Zhou","year":"2021","journal-title":"Cancer Res."},{"key":"B178","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/s0092-8674(00)81879-6","article-title":"CDK-independent activation of estrogen receptor by cyclin D1","volume":"88","author":"Zwijsen","year":"1997","journal-title":"Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1549520\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T02:07:42Z","timestamp":1747015662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1549520\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":178,"alternative-id":["10.3389\/fphar.2025.1549520"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1549520","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"article-number":"1549520"}}